Study guide
36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis
Key Takeaways Explain This Topic AI
Asymptomatic gallstones discovered incidentally require expectant observation without prophylactic cholecystectomy, except in high-risk conditions: calcified porcelain gallbladder, gallstones >3 cm in diameter, or hemolytic hemoglobinopathies (e.g., sickle cell disease).
Biliary colic is characterized by episodic, postprandial RUQ or epigastric pain lasting 30 minutes to 6 hours that resolves completely with normal laboratory tests and vitals; in contrast, acute cholecystitis features persistent cystic duct obstruction with severe pain lasting >6 hours, fever, leukocytosis, and sonographic wall thickening >3 mm or pericholecystic fluid.
Cholescintigraphy (HIDA scan) is the gold-standard test when ultrasound is equivocal for acute cholecystitis: failure of the radiotracer (Tc-99m) to visualize the gallbladder within 4 hours confirms cystic duct obstruction; early laparoscopic cholecystectomy within 24 to 72 hours of admission is the definitive treatment of choice.
Acute cholangitis is an emergency diagnosed by Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad (adding shock and altered mental status in toxic suppurative cholangitis); management requires emergency resuscitation, broad-spectrum IV antibiotics, and urgent biliary decompression via ERCP within 24 hours.
Acute pancreatitis diagnosis requires at least 2 of 3 Revised Atlanta criteria: epigastric pain radiating to the back, serum lipase >=3x ULN, and characteristic cross-sectional imaging; management centers on aggressive goal-directed Lactated Ringer's resuscitation (200-500 mL/h), early oral refeeding with a low-fat diet, strict avoidance of prophylactic antibiotics (even in sterile necrosis), and same-admission cholecystectomy for gallstone pancreatitis.
Last updated: September 2026
Spectrum of Gallbladder & Biliary Tract Diseases
Gallstone disease (cholelithiasis) affects over 20 million adults in the United States, representing one of the leading causes of ambulatory gastrointestinal visits and hospital admissions. The clinical spectrum spans from benign, silent gallstones to life-threatening ascending biliary sepsis.
Gallstone Pathogenesis & Classification
Cholesterol Gallstones (75% to 80% of Cases) : Formed when hepatic secretion of cholesterol exceeds the solubilizing capacity of bile salts and phospholipids (lecithin), leading to cholesterol supersaturation, accelerated crystal nucleation, and gallbladder hypomotility. Major risk factors are summarized by the classic mnemonic: Female, Forty, Fertile, and Fat (multiparity/estrogen exposure, obesity, rapid weight loss/bariatric surgery, and fibrate therapy).
Black Pigment Gallstones (10% to 15% of Cases) : Composed of calcium bilirubinate polymers. Driven by high concentrations of unconjugated bilirubin resulting from chronic hemolysis (sickle cell anemia, hereditary spherocytosis, beta-thalassemia major, malaria) and advanced cirrhosis (impaired bilirubin glucuronidation).
Brown Pigment Gallstones (<5% of Cases) : Form de novo within the intrahepatic or extrahepatic bile ducts in the presence of chronic biliary stasis and bacterial/parasitic infection ( Escherichia coli , Klebsiella , Clonorchis sinensis ). Bacterial beta-glucuronidase hydrolyzes conjugated bilirubin into insoluble unconjugated bilirubin precipitates.
Asymptomatic Cholelithiasis: Management & High-Risk Exceptions
Natural History : Gallstones are discovered incidentally during routine abdominal imaging in 10% to 20% of adults. Approximately 60% to 80% remain completely asymptomatic throughout life, with only 1% to 2% per year progressing to symptomatic biliary colic.
Management : Expectant observation (watchful waiting) is the universal standard of care. Prophylactic cholecystectomy is NOT recommended because the risks of general anesthesia and surgical bile duct injury outweigh the lifetime risk of developing symptomatic disease.
Specific High-Risk Exceptions Mandating Prophylactic Cholecystectomy :
Porcelain Gallbladder : Extensive transmural calcification of the gallbladder wall secondary to chronic inflammation; historically associated with a high incidence (up to 2% to 15%) of aggressive gallbladder adenocarcinoma.
Large Gallstones (>3 cm in Diameter) : Carry a tenfold increased risk of gallbladder carcinoma and a markedly increased risk of erosion into adjacent duodenum, causing cholecystoenteric fistula and mechanical gallstone ileus .
Hemolytic Hemoglobinopathies : Sickle cell disease and hereditary spherocytosis, where rapid pigment stone formation and recurrent biliary colic confound the diagnosis of acute vaso-occlusive abdominal crises.
Anomalous Pancreaticobiliary Duct Junction or gallbladder polyps >10 mm.
Biliary Colic vs. Acute Cholecystitis
Differentiating uncomplicated biliary colic from acute cholecystitis is one of the most critical clinical decision points in ambulatory practice.
Comparison Table: Biliary Colic vs. Acute Cholecystitis
Clinical Parameter Uncomplicated Biliary Colic Acute Calculous Cholecystitis
Pathophysiologic Mechanism Transient mechanical impaction of a gallstone in the gallbladder neck or cystic duct during postprandial CCK-mediated contraction Sustained, persistent cystic duct obstruction (>6 hours) leading to luminal distension, mucosal ischemia, chemical inflammation, and secondary bacterial infection
Pain Character & Duration Severe, steady, aching RUQ/epigastric visceral pain; lasts 30 minutes to 6 hours ; resolves spontaneously Severe, unremitting, sharp RUQ somatic pain; persists >6 hours (often lasting several days without treatment)
Radiation Radiates to right inferior scapular angle (Boas sign) or right shoulder Radiates to right infrascapular area and right shoulder tip (phrenic nerve irritation)
Systemic Features & Vitals Afebrile ; completely normal heart rate and blood pressure Fever (low-grade 38.0–38.5°C), tachycardia, anorexia, nausea, recurrent vomiting
Physical Examination Abdomen soft; mild focal RUQ tenderness; Murphy sign is NEGATIVE ; no guarding Marked localized RUQ tenderness; involuntary guarding; Murphy sign is POSITIVE
Laboratory Evaluation Completely normal : normal WBC, normal bilirubin, normal AST/ALT/ALP, normal lipase Leukocytosis (WBC 12,000–15,000/mcL with left shift); mild AST/ALT/ALP elevation; total bilirubin typically <2-3 mg/dL
Ultrasound Findings Gallstones present; gallbladder wall normal (<=3 mm); no pericholecystic fluid; negative sonographic Murphy sign Gallstones; wall thickening >3 mm ; pericholecystic fluid ; sonographic Murphy sign positive ; hydropic distension
Definitive Treatment Outpatient elective laparoscopic cholecystectomy; acute pain managed with oral/IV NSAIDs Hospital admission; NPO, IV fluids, IV broad-spectrum antibiotics; early laparoscopic cholecystectomy within 24–72 hours
Diagnostic Evaluation of Acute Cholecystitis
First-Line Imaging: Transabdominal Ultrasound :
Sensitivity ~88%, specificity ~80%. Cardinal diagnostic findings include: 1) Gallstones with acoustic shadowing; 2) Gallbladder wall thickening >3 mm ; 3) Pericholecystic fluid halo ; 4) Gallbladder hydrops (transverse diameter >4 cm); and 5) Sonographic Murphy sign (exquisite tenderness localized precisely when the ultrasound transducer compresses the visualized gallbladder; positive predictive value >90%).
Diagnostic Gold Standard: Cholescintigraphy (HIDA Scan) :
Utilizes Technetium-99m labeled iminodiacetic acid derivatives (mebrofenin or disofenin). The radiotracer is extracted by hepatocytes, excreted into the biliary tree, and normally enters the gallbladder and duodenum within 1 hour.
Positive HIDA Scan Criteria : The liver, common bile duct, and small bowel are clearly visualized, but the gallbladder fails to visualize at 1 and 4 hours (or within 30 minutes following intravenous morphine administration to increase sphincter of Oddi tone). Non-visualization conclusively confirms cystic duct obstruction , establishing the diagnosis of acute cholecystitis with sensitivity and specificity >95%.
Laboratory Red Flag: Elevated Total Bilirubin :
Uncomplicated acute cholecystitis causes at most mild hyperbilirubinemia (<2.0 to 3.0 mg/dL). If total bilirubin is >4.0 mg/dL or clinical jaundice is present, the clinician must urgently suspect coexisting choledocholithiasis (common bile duct stone) or Mirizzi syndrome (a large stone impacted in the cystic duct neck causing extrinsic mechanical compression of the adjacent common hepatic duct).
Tokyo Guidelines 2018 (TG18) & Surgical Timing
Severity Classification :
Grade I (Mild) : Acute cholecystitis in a healthy patient without organ dysfunction and mild inflammatory changes.
Grade II (Moderate) : Accompanied by any of: marked leukocytosis (WBC >18,000/mcL), palpable tender RUQ mass, symptom duration >72 hours, or marked local inflammation (gangrenous cholecystitis, emphysematous cholecystitis, pericholecystic abscess).
Grade III (Severe) : Complicated by organ dysfunction (cardiovascular hypotension requiring vasopressors, neurologic altered consciousness, respiratory PaO2/FiO2 <300, renal oliguria/Cr >2.0 mg/dL, hepatic INR >1.5, or thrombocytopenia <100,000/mcL).
Timing of Cholecystectomy (Critical Board Concept) :
Early laparoscopic cholecystectomy performed within 24 to 72 hours of hospital admission is the gold-standard treatment for Grade I and II cholecystitis.
Large multicenter randomized trials have proven that early cholecystectomy is vastly superior to traditional delayed interval cholecystectomy (waiting 6 to 8 weeks). Early surgery significantly reduces total hospital stay, eliminates interval gallstone complications (recurrent cholecystitis, gallstone pancreatitis), reduces overall medical costs, and carries equivalent bile duct injury and complication rates.
- Acute Acalculous Cholecystitis & Acute Cholangitis
- Acute Acalculous Cholecystitis
Pathophysiology : Severe necroinflammatory disease of the gallbladder occurring in the absence of gallstones . Typically develops in critically ill, hospitalized patients: severe thermal burns, polytrauma, major non-biliary surgery, septic shock, prolonged mechanical ventilation, and long-term total parenteral nutrition (TPN). Driven by profound microvascular ischemia (hypoperfusion, shock) combined with severe biliary stasis (lack of enteral CCK stimulation causing thick, inspissated, toxic bile).
Clinical Presentation : High mortality rate (30% to 50%) due to rapid progression to gangrene, empyema, and perforation. Patients are frequently intubated or non-verbal; manifests as unexplained fever, escalating leukocytosis, sepsis, or jaundice without an obvious source.
Diagnosis : Bedside ultrasound shows gallbladder wall thickening >3 mm, pericholecystic fluid, subserosal edema, and absence of cholelithiasis.
Management : Emergent broad-spectrum IV antibiotics and bedside percutaneous transhepatic cholecystostomy (PTC) tube drainage . PTC provides immediate source control without requiring high-risk general anesthesia and emergent laparotomy.
Acute Cholangitis: Charcot Triad & Reynolds Pentad
Pathophysiology : Ascending bacterial infection of the biliary ductal system in the setting of complete or partial biliary outflow obstruction. The leading etiology is choledocholithiasis (70%), followed by benign/malignant strictures (pancreatic cancer, cholangiocarcinoma) and occluded biliary stents.
Biliary Pressure Dynamics : Biliary obstruction causes intrabiliary pressure to exceed 20 to 25 cm H2O. This high pressure disrupts the blood-biliary barrier (tight junctions between cholangiocytes and hepatocytes), permitting rapid translocation of colonized enteric bacteria ( E. coli , Klebsiella pneumoniae , Enterobacter , Enterococcus ) into hepatic sinusoids and the systemic circulation, causing bacteremia and septic shock.
Clinical Features :
Charcot Triad : 1) High fever with rigors; 2) Jaundice; 3) RUQ abdominal pain. Present in 50% to 70% of patients.
Reynolds Pentad : Charcot triad PLUS 4) Hypotension (Septic Shock) ; 5) Altered Mental Status (Confusion / Delirium) . Defines acute toxic suppurative cholangitis ; without immediate decompression, mortality approaches 100%!
Management Protocol :
- Immediate ICU admission and aggressive isotonic crystalloid resuscitation;
- Broad-spectrum IV antibiotics (piperacillin-tazobactam 3.375–4.5 g IV Q8H or meropenem 1 g IV Q8H);
Emergency Biliary Decompression : Urgent Endoscopic Retrograde Cholangiopancreatography (ERCP) with endoscopic biliary sphincterotomy and stone extraction / stent placement within 24 hours (or percutaneous transhepatic biliary drainage / PTBD if ERCP is unavailable). Emergent open surgical common bile duct exploration carries prohibitive mortality and is avoided.
Acute Pancreatitis: Revised Atlanta Classification & Diagnostic Principles
Acute pancreatitis is an acute inflammatory process of the pancreatic parenchyma characterized by premature intracellular activation of digestive zymogens, resulting in autodigestion, microvascular thrombosis, and local and systemic inflammation.
The Revised Atlanta Diagnostic Criteria
Diagnosis requires fulfilling at least two of the following three criteria :
Characteristic Abdominal Pain : Acute onset of severe, persistent, steady epigastric pain that frequently radiates straight through to the back (described as boring or band-like, worsened by lying supine and partially relieved by sitting forward with knees flexed);
Serum Lipase or Amylase Elevation >=3 Times the Upper Limit of Normal (ULN) ;
Characteristic Findings on Cross-Sectional Imaging : Contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI), or transabdominal ultrasound.
Lipase vs. Amylase: Clinical Pearls
Serum Lipase is Markedly Superior : Lipase is secreted almost exclusively by pancreatic acinar cells, whereas amylase is produced by salivary glands, ovaries, fallopian tubes, and adipose tissue. Lipase rises within 4 to 8 hours of onset, peaks at 24 hours, and remains elevated for 8 to 14 days (due to renal tubular reabsorption), whereas amylase normalizes rapidly within 3 to 5 days. Lipase sensitivity is 95% to 100% and specificity is 99%.
Diagnostic Pitfall : Serum amylase can be falsely normal in alcohol-induced pancreatitis and in severe hypertriglyceridemic pancreatitis (due to an uncharacterized circulating inhibitor that interferes with calorimetric amylase assays). Macroamylasemia causes chronic hyperamylasemia with completely normal lipase and no pancreatic disease.
Serial Enzyme Monitoring : Once acute pancreatitis is diagnosed, serial monitoring of lipase or amylase is of zero clinical utility ! Lipase concentrations do not correlate with disease severity, clinical progression, complication development, or readiness for discharge.
Indications & Timing of Abdominal CT Imaging
Routine Early CT is NOT Indicated : In a patient presenting with classic epigastric pain and lipase >=3x ULN, contrast-enhanced abdominal CT on admission is NOT indicated ! Early CT (<48 to 72 hours) does not alter clinical management, exposes the patient to radiation and nephrotoxic contrast, and underestimates the true extent of pancreatic necrosis, which takes 72 to 96 hours to demarcate fully.
Valid Indications for Contrast-Enhanced CT :
Diagnostic ambiguity (e.g., atypical pain, lipase not meeting 3x ULN, or need to exclude mesenteric ischemia or perforated viscous);
Clinical deterioration or lack of clinical improvement after 48 to 72 hours of aggressive medical therapy;
Sepsis or multi-organ failure developing after 72 hours, to detect local complications: acute peripancreatic fluid collections (APFC), acute necrotic collection (ANC), walled-off necrosis (WON), or pseudocysts.
Etiologies: The 'I GET SMASHED' Framework ACUTE PANCREATITIS ETIOLOGIES
- I ──> Idiopathic (10-20%; often occult biliary microlithiasis/sludge)
- G ──> Gallstones (40-50%; leading cause; stones <5mm traverse cystic duct)
- E ──> Ethanol (30%; requires chronic heavy use >50 g/day for >=5 years)
- T ──> Trauma (blunt abdominal, steering wheel, bicycle handlebars)
- S ──> Steroids & Autoimmune (Autoimmune pancreatitis: IgG4-related AIP)
- M ──> Mumps & Viruses (Coxsackie B, CMV, EBV, HAV/HBV, HIV)
- A ──> Autoimmune / Anatomical (Pancreas divisum, annular pancreas)
- S ──> Scorpion venom (Tityus trinitatis sting)
- H ──> Hypertriglyceridemia (>1,000 mg/dL) & Hypercalcemia (hyperparathyroidism)
- E ──> ERCP (post-ERCP pancreatitis in 3-10%; prevent with rectal indomethacin)
- D ──> Drugs (Azathioprine, 6-MP, valproate, thiazides, estrogens, DPP-4/GLP-1)
Gallstone Pancreatitis (40% to 50%) : Small gallstones (<5 mm) slip through the cystic duct into the common bile duct, lodging transiently at the ampulla of Vater. This creates transient common channel reflux of bile into the pancreatic duct or raises pancreatic ductal hypertension, initiating zymogen activation.
Hypertriglyceridemia-Induced Pancreatitis (1% to 4%) : Occurs when fasting serum triglycerides exceed 1,000 mg/dL (11.3 mmol/L). Pancreatic lipase hydrolyzes triglycerides into toxic, unbound free fatty acids that induce acinar cell lysis, microvascular thrombosis, and capillary ischemia. Serum appears lactescent/milky. Management involves continuous intravenous regular insulin infusion (0.1 units/kg/h) with 5% or 10% dextrose to activate endothelial lipoprotein lipase, and therapeutic plasma exchange (plasmapheresis) in severe cases.
Post-ERCP Pancreatitis (PEP) : Occurs in 3% to 10% of cases. Proven prevention: prophylactic rectal indomethacin (100 mg PR) administered immediately before or after the procedure, combined with temporary pancreatic duct stenting.
- Severity Stratification & Comprehensive Inpatient Management
- Severity Classification (Revised Atlanta)
Mild Acute Pancreatitis : Absence of organ failure and absence of local or systemic complications. Resolves in 3 to 5 days; mortality <1%.
Moderately Severe Acute Pancreatitis : Transient organ failure that resolves within 48 hours, OR local/systemic complications without persistent organ failure.
Severe Acute Pancreatitis : Persistent organ failure lasting >48 hours involving one or more systems: respiratory (PaO2/FiO2 <=300), renal (serum creatinine >=2.0 mg/dL or doubling), or cardiovascular (systolic BP <90 mmHg unresponsive to fluids). Mortality rate is 15% to 30%.
The BISAP Score (Bedside Index for Severity in Acute Pancreatitis)
Calculated within the first 24 hours of admission (1 point each; score 0 to 5):
- B - BUN >25 mg/dL (8.9 mmol/L);
- I - Impaired mental status (Glasgow Coma Scale <15 or confusion);
- S - SIRS (>=2 of: temp >38°C or <36°C, HR >90 bpm, RR >20, WBC >12k or <4k or >10% bands);
- A - Age >60 years;
P - Pleural effusion present on imaging.
Interpretation : BISAP 0-2 = low mortality (<1-2%); BISAP 3-5 = high risk of persistent organ failure and mortality (>15-20%).
Evidence-Based Inpatient Management Protocol
Aggressive Goal-Directed Crystalloid Hydration :
Fluid of Choice: Lactated Ringer's (LR) is superior to 0.9% Normal Saline. Normal saline induces hyperchloremic metabolic acidosis and worsens pancreatic inflammation, whereas LR reduces systemic inflammation (SIRS) and lower CRP at 24 hours.
Infusion Rates : Initial infusion of 200 to 500 mL/hour (or an initial bolus of 10 to 20 mL/kg followed by 200-250 mL/h) during the first 12 to 24 hours.
Goal-Directed Targets (Re-evaluated every 6-12 hours) : Urine output >0.5 to 1.0 mL/kg/hour, Mean Arterial Pressure (MAP) 65 to 85 mmHg, reduction in BUN, and normalization of hematocrit toward 35% to 40%.
Hemoconcentration Pearl : Admission hematocrit >44% or failure of hematocrit to fall at 24 hours indicates severe intravascular volume depletion and correlates with pancreatic necrosis.
Caution : Avoid over-hydration in patients with underlying congestive heart failure or end-stage renal disease.
Multimodal Analgesia :
Intravenous opioids (hydromorphone or fentanyl) are first-line for severe pain. The historic dogma that morphine causes sphincter of Oddi spasm is a laboratory artifact with zero proven clinical detriment; morphine is fully acceptable.
Nutritional Support: Early Oral Refeeding Paradigm :
The historical dogma of prolonged 'bowel rest / NPO' until pain and labs resolve is obsolete and harmful.
In mild acute pancreatitis, early oral refeeding with a low-fat solid or liquid diet should be initiated as soon as severe pain improves, nausea/vomiting resolves, and ileus clears (usually within 24 to 48 hours of admission).
There is NO requirement to wait for lipase or amylase levels to normalize before feeding!
Early enteral feeding maintains gut mucosal barrier integrity, prevents bacterial translocation from the colon into the bloodstream, and significantly reduces infected necrosis, multi-organ failure, and death.
If oral intake is not tolerated after several days, enteral tube feeding (nasogastric or nasojejunal) is vastly superior to Total Parenteral Nutrition (TPN) . TPN is associated with gut mucosal atrophy, central line infections, and increased mortality.
Antibiotic Stewardship: Strictly NO Prophylactic Antibiotics :
Routine prophylactic antibiotics are NOT recommended in acute pancreatitis, regardless of disease severity or whether CT demonstrates sterile necrotizing pancreatitis!
Prophylactic antibiotics do not decrease infected necrosis or mortality, but significantly increase the risk of multi-drug-resistant bacterial and opportunistic fungal superinfections ( Candida ).
Therapeutic antibiotics (carbapenems [meropenem 1 g IV Q8H], which penetrate pancreatic tissue) are indicated ONLY for confirmed or strongly suspected infected pancreatic necrosis (extraluminal gas on CT or CT-guided aspirate demonstrating bacteria) or extrapancreatic infections (cholangitis, bacteremia, pneumonia, UTI).
Surgical Timing: Same Index Admission Cholecystectomy :
In all patients with mild gallstone pancreatitis, laparoscopic cholecystectomy MUST be performed during the SAME index hospital admission once acute pancreatitis symptoms have resolved.
Discharging patients for 'delayed elective cholecystectomy' results in a disastrous 25% to 30% recurrence rate of recurrent pancreatitis, acute cholecystitis, or cholangitis within 30 to 60 days !
In severe necrotizing pancreatitis, cholecystectomy is deferred until systemic inflammation subsides and necrotic collections stabilize.